HOME
SEARCH
RSS FEED
SUBSCRIBE
Detection of Retroviruses and HIV-1 Groups -M and -O Discrimination within Clinical Serum Samples
Case ID:
TAB-2738
Web Published:
12/6/2022
Description:
CDC researchers have developed methods for detecting retroviruses within a patient blood sample and discriminating HIV-1 samples within serum specimens. HIV-1 can be genetically classified into two major groups, group M (major) and Group O (outlier) with group O comprising all divergent viruses that do not cluster with group M. The identification of group O infections raised public health concerns about the safety of the blood supply because HIV-1 screening by group M-based serologic tests does not consistently detect group O infection.
The assay is based on the selective inhibition of Amp-RT reactivity of Group M viruses by nevirapine, a non-nucleoside RT inhibitor. Group O viruses can be generically identified by the resistance of their Amp-RT activity to nevirapine. The assay can be used to screening of the blood supply and to rapidly differentiate group M from group O virus.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Detection_of_Retroviruses_and_HIV-1_ Groups_-M_and_-O_Discrimination_within_Clinical_Serum_Samples
Category(s):
Licensing
Research Materials
Diagnostics
Occupational Safety and Health
Therapeutics
Infectious Disease
Consumer Products
Bookmark this page
Download as PDF
For Information, Contact:
Inteum Admin
NIH Technology Transfer
Inventors:
Thomas Folks
Shinji Yamamoto
William Switzer
Walid Heneine
Keywords:
Activity
assay
CDC Docket Import
CDC Docket Import CDC Prosecuting
DA4AXX
DA4XXX
DAXXXX
Detection
DXXXXX
Methods
OID-NCHHSTP-DHPSE
Reverse
RT
SENSITIVE
TRANSCRIPTASE
VLXXXX
WBXXXX
WFXXXX
WIXXXX
XCXXXX
XEXXXX
YBXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum